Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15002.

Article  PubMed  Google Scholar 

Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984;27:645–53.

Article  CAS  PubMed  Google Scholar 

Hügle T, O’Reilly S, Simpson R, Kraaij MD, Bigley V, Collin M, et al. Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum. 2013;65:481–91.

Article  PubMed  PubMed Central  Google Scholar 

Lescoat A, Lecureur V, Varga J. Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications. Curr Opin Rheumatol. 2021;33:463–70.

Article  CAS  PubMed  Google Scholar 

Lescoat A, Lecureur V, Roussel M, Sunnaram BL, Ballerie A, Coiffier G, et al. CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis. Clin Rheumatol. 2017;36:1649–54.

Article  PubMed  Google Scholar 

Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005;26:587–95.

Article  CAS  PubMed  Google Scholar 

O’Reilly S, Hügle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology. 2012;51:1540–9.

Article  PubMed  Google Scholar 

Distler JHW, Györfi AH, Ramanujam M, Whitfield ML, Königshoff M, Lafyatis R. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol. 2019;15:705–30.

Article  CAS  PubMed  Google Scholar 

Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, Khanna D. Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies. Clin Rev Allergy Immunol. 2021. https://doi.org/10.1007/s12016-021-08891-0.

Article  PubMed  Google Scholar 

Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640–4.

Article  CAS  PubMed  Google Scholar 

Kim KW, Vallon-Eberhard A, Zigmond E, Farache J, Shezen E, Shakhar G, et al. In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood. 2011;118:e156–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521–30.

Article  CAS  PubMed  Google Scholar 

Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998;188:1413–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ancuta P, Rao R, Moses A, Mehle A, Shaw SK, Luscinskas FW, et al. Fractalkine preferentially mediates arrest and migration of CD16 + monocytes. J Exp Med. 2003;197:1701–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benyamine A, Magalon J, Cointe S, Lacroix R, Arnaud L, Bardin N, et al. Increased serum levels of fractalkine and mobilisation of CD34(+)CD45(-) endothelial progenitor cells in systemic sclerosis. Arthritis Res Ther. 2017;19:60.

Article  PubMed  PubMed Central  Google Scholar 

Hasegawa M, Sato S, Echigo T, Hamaguchi Y, Yasui M, Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis. 2005;64:21–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arai M, Ikawa Y, Chujo S, Hamaguchi Y, Ishida W, Shirasaki F, et al. Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. J Dermatol Sci. 2013;69:250–8.

Article  CAS  PubMed  Google Scholar 

Luong VH, Utsunomiya A, Chino T, Doanh LH, Matsushita T, Obara T, et al. Inhibition of the progression of skin inflammation, fibrosis, and Vascular Injury by Blockade of the CX3CL1/CX3CR1 pathway in experimental mouse models of systemic sclerosis. Arthritis Rheumatol. 2019;71:1923–34.

Article  CAS  PubMed  Google Scholar 

Yamamoto T. Characteristics of animal models for scleroderma. Curr Rheumatol Rev. 2005;1:101–9.

Article  CAS  Google Scholar 

Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, et al. Memory CD4 + T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112:101–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsushita T, Date M, Kano M, Mizumaki K, Tennichi M, Kobayashi T, et al. Blockade of p38 mitogen-activated protein kinase inhibits murine Sclerodermatous Chronic Graft-versus-host disease. Am J Pathol. 2017;187:841–50.

Article  CAS  PubMed  Google Scholar 

Huu DL, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, et al. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. Arthritis Rheum. 2013;65:1624–35.

Article  CAS  PubMed  Google Scholar 

Ueha S, Murai M, Yoneyama H, Kitabatake M, Imai T, Shimaoka T, et al. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-tumor effects. J Leukoc Biol. 2007;81:176–85.

Article  CAS  PubMed  Google Scholar 

Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, et al. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol. 2004;173:7010–6.

Article  CAS  PubMed  Google Scholar 

Kuboi Y, Nishimura M, Ikeda W, Nakatani T, Seki Y, Yamaura Y, et al. Blockade of the Fractalkine-CX3CR1 Axis ameliorates experimental colitis by dislodging venous crawling monocytes. Int Immunol. 2019;31:287–302.

Article  CAS  PubMed  Google Scholar 

Hoshino-Negishi K, Ohkuro M, Nakatani T, Kuboi Y, Nishimura M, Ida Y, et al. Role of anti-fractalkine antibody in suppression of Joint Destruction by Inhibiting Migration of Osteoclast precursors to the synovium in experimental arthritis. Arthritis Rheumatol. 2019;71:222–31.

Article  CAS  PubMed  Google Scholar 

Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, et al. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol. 2012;132:2752–61.

Article  PubMed  Google Scholar 

Utsunomiya A, Chino T, Kasamatsu H, Hasegawa T, Utsunomiya N, Luong VH, et al. The compound LG283 inhibits bleomycin-induced skin fibrosis via antagonizing TGF-β signaling. Atthritis Res. 2022;24:94.

Article  CAS  Google Scholar 

Kishida N, Maki T, Takagi Y, Yasuda K, et al. Role of Perivascular Oligodendrocyte Precursor Cells in Angiogenesis after Brain Ischemia. J Am Heart Assoc. 2019;8:e011824. https://doi.org/10.1161/JAHA.118.011824.

Article  PubMed  PubMed Central  Google Scholar 

Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD, et al. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis. 2020;79:379–86.

Article  CAS  PubMed  Google Scholar 

Kania G, Rudnik M, Distler O. Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis. Nat Rev Rheumatol. 2019;15:288–302.

Article  PubMed  Google Scholar 

Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE, Luedde T, et al. The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology. 2010;52:1769–82.

Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood. 2009;113:963–72.

Article  CAS  PubMed  Google Scholar 

Ishida Y, Kimura A, Nosaka M, Kuninaka Y, Hemmi H, Sasaki I, et al. Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration. Sci Rep. 2017;7:16833.

Article  PubMed  PubMed Central  Google Scholar 

Zhang P, Wang BJ, Wang JZ, Xie XM, Tong QX. Association of CX3CL1 and CX3CR1 expression with liver fibrosis in a mouse model of Schistosomiasis. Curr Med Sci. 2020;40:1121–7.

Article  CAS  PubMed  Google Scholar 

von Vietinghoff S, Kurts C. Regulation and function of CX3CR1 and its ligand CX3CL1 in kidney disease. Cell Tissue Res. 2021;385:335–44.

Article  Google Scholar 

Shimizu K, Furuichi K, Sakai N, Kitagawa K, Matsushima K, Mukaida N, et al. Fractalkine and its receptor, CX3CR1, promote hypertensive interstitial fibrosis in the kidney. Hypertens Res. 2011;34:747–52.

Article